EGRIFTA WR is not for weight loss management
24 weeks (full titration) 2 x 30 mg vials (or 5-6 x 10 mg) Maintenance at 15 mg/week uses one 30 mg vial every 2 weeks
(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB
NanoBRET DNA constructs For nanoBRET experiments, we used receptor constructs consisting of either human D2R ( DRD2 ) and rat 2A -adrenergic receptor ( Adra2a ) cDNAs fused to HaloTag at the C-terminus ( 2A -AR-HaloTag and D2R-HaloTag)
Molecular Formula & Weight: Proprietary peptide sequence
Centella asiatica extracts containing madecassoside and asiaticoside have a long-established role in post-procedural skincare
